Technical Analysis for CUE - Cue Biopharma, Inc.

Grade Last Price % Change Price Change
grade B 6.15 1.99% 0.12
CUE closed up 1.99 percent on Thursday, January 17, 2019, on 66 percent of normal volume.
2 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical CUE trend table...

Date Alert Name Type % Chg
Jan 17 Spinning Top Other 0.00%
Jan 17 Wide Bands Range Expansion 0.00%
Jan 16 Crossed Above 50 DMA Bullish 1.99%
Jan 16 180 Bullish Setup Bullish Swing Setup 1.99%
Jan 16 Wide Bands Range Expansion 1.99%
Jan 15 Fell Below 50 DMA Bearish 12.64%
Jan 15 Wide Bands Range Expansion 12.64%
Jan 15 Overbought Stochastic Strength 12.64%
Jan 15 Down 3 Days in a Row Weakness 12.64%
Jan 15 Gapped Down Weakness 12.64%

Older signals for CUE ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Track My Stocks
Configure default chart indicators
Basic chart:
Profile
  • Earnings date: 2018-12-17
Cue Biopharma Inc is a biopharmaceutical company developing a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders.
Is CUE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Jan 16 Cue Biopharma Announces Presentation Highlighting Immuno-STAT Platform and CUE-101 at the 2019 Keystone Symposia Conference
Jan 7 3 Stock Charts for Monday: Gap, CenterPoint Energy and Boston Scientific
Jan 5 Cue Biopharma files for $150M mixed shelf offering
Dec 27 Avadel Pharmaceuticals and Novus Therapeutics among healthcare gainers; Spectrum Pharmaceuticals leads the losers
Dec 20 Cue Biopharma and LG Chem Life Sciences Announce WT1 as the Next Immuno-STAT™ Target in Oncology
Dec 17 Cue Biopharma, Gravitating Near Concerning Market Participants
Nov 21 Cue Biopharma, Inc. (CUE) CEO Dan Passeri on Q3 2018 Results - Earnings Call Transcript
Nov 20 The Daily Biotech Pulse: Denali's Positive Results, Novartis' Substance Abuse Therapy Launch, Medtronic Earnings
Nov 19 Cue Biopharma beats on revenue
Nov 15 The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results
See more CUE news...
Indicators
Indicator Value
52 Week High 17.99
52 Week Low 4.16
Average Volume 117,627
200-Day Moving Average 9.3905
50-Day Moving Average 5.4738
20-Day Moving Average 5.373
10-Day Moving Average 5.941
Average True Range 0.5756
ADX 17.5
+DI 22.8824
-DI 19.3179
Chandelier Exit (Long, 3 ATRs ) 5.0932
Chandelier Exit (Short, 3 ATRs ) 5.8868
Upper Bollinger Band 6.7668
Lower Bollinger Band 3.9792
Percent B (%b) 0.78
BandWidth 51.88163
MACD Line 0.2324
MACD Signal Line 0.1253
MACD Histogram 0.1071
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.89
Resistance 3 (R3) 6.86 6.58 6.76
Resistance 2 (R2) 6.58 6.40 6.60 6.72
Resistance 1 (R1) 6.37 6.28 6.48 6.40 6.68
Pivot Point 6.09 6.09 6.15 6.11 6.09
Support 1 (S1) 5.88 5.91 5.99 5.91 5.62
Support 2 (S2) 5.60 5.79 5.62 5.58
Support 3 (S3) 5.39 5.60 5.54
Support 4 (S4) 5.42